methylphenidate metadate cd (UCB SA Inc)
90
Structured Review
UCB SA Inc
methylphenidate metadate cd
Methylphenidate Metadate Cd, supplied by UCB SA Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/metadate+cd/metadate+cd/pmc09227027-44-6-10
Average 90 stars, based on 1 article reviews
Methylphenidate Metadate Cd, supplied by UCB SA Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/metadate+cd/metadate+cd/pmc09227027-44-6-10
Average 90 stars, based on 1 article reviews
methylphenidate metadate cd - by Bioz Stars,
2026-09
90/100 stars
Images
1) Product Images from "Review on Starter Pellets: Inert and Functional Cores"
Article Title: Review on Starter Pellets: Inert and Functional Cores
Journal: Pharmaceutics
doi: 10.3390/pharmaceutics14061299
Figure Legend Snippet: Examples of starter pellet formulations used in different dosage forms worldwide.
Techniques Used: Capsules, Starch, Suspension
Related Articles
Clinical Proteomics:Article Title: Safety and efficacy considerations due to misuse of extended-release formulations of stimulant medications. Article Snippet: Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ipgm20 Download by: [La Trobe University] Date: 29 July 2016, At: 13:15 Postgraduate Medicine ISSN: 0032-5481 (Print) 1941-9260 (Online) Journal homepage: http://www.tandfonline.com/loi/ipgm20 Safety and efficacy considerations due to misuse of extended-release formulations of stimulant medications Rakesh Jain & Jeffrey G. Stark To cite this article: Rakesh Jain & Jeffrey G. Stark (2016): Safety and efficacy considerations due to misuse of extended-release formulations of stimulant medications, Postgraduate Medicine, DOI: 10.1080/00325481.2016.1218259 To link to this article: http://dx.doi.org/10.1080/00325481.2016.1218259 Accepted author version posted online: 28 Jul 2016.. Published online: 28 Jul 2016.. Submit your article to this journal View related articles View Crossmark data Article Type: Review Safety and efficacy considerations due to misuse of extended-release formulations of stimulant medications Rakesh Jain;1 and Jeffrey G. Stark2 1Department of Psychiatry, Texas Tech Health Sciences Center Medical School at Permian Basin, Midland, Texas, USA; 2Worldwide Clinical Trials, Austin, Texas, USA Running head: misuse of stimulant medications Formulation:Article Title: The use of modified-release methylphenidate in the treatment of attention-deficit/hyperactivity disorder. Article Snippet: INTRODUCTION: Since Ritalin® (Methylphenidate-Immediate release or MPH-IR) was introduced for the treatment of attention-deficit/hyperactivity disorder, multiple formulations of MPH have been developed.. The specific formulation determines the pharmacokinetic (PK) profile and the onset and duration of action for the compound.. AREAS COVERED: Aptensio XR® is a multilayer-release MPH (MPH-MLR) consisting of an MPH-IR layer (40%) and an extended-release (ER) portion of 60% of MPH. other:Article Title: Method for treating ADD or ADHD comprising administering amphetamine complexed with ion-exchange resin particles Article Snippet: Treatment C: Reference Product METADATE CD Article Title: Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis Article Snippet: Provigil - Cephalon (currently owned by Reva Pharmaceuticals) http://www.tevausa.com/ Drug manufactures contacted to gather additional data/information and query about any additional study not retrieved in our search: 1. Article Title: Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6–12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting Article Snippet: To be eligible for the study, participants were required to have had a positive response to a stable dose of Article Title: Pharmacokinetics of a New Amphetamine Extended-release Oral Liquid Suspension Under Fasted and Fed Conditions in Healthy Adults: A Randomized, Open-label, Single-dose, 3-treatment Study. Article Snippet: & 2017 Elsevier HS Journals, Inc. All rights reserved.. ABSTRACT Purpose: A new amphetamine extended-release liquid formulation (AMP XR-OS), intended for the treatment of attention-deficit/hyperactivity disorder, has been developed.. This study was performed to determine if administration with food affected the rate of absorption or bioavailability of AMP XR-OS. Capsules:Article Title: Safety and efficacy considerations due to misuse of extended-release formulations of stimulant medications. Article Snippet: Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ipgm20 Download by: [La Trobe University] Date: 29 July 2016, At: 13:15 Postgraduate Medicine ISSN: 0032-5481 (Print) 1941-9260 (Online) Journal homepage: http://www.tandfonline.com/loi/ipgm20 Safety and efficacy considerations due to misuse of extended-release formulations of stimulant medications Rakesh Jain & Jeffrey G. Stark To cite this article: Rakesh Jain & Jeffrey G. Stark (2016): Safety and efficacy considerations due to misuse of extended-release formulations of stimulant medications, Postgraduate Medicine, DOI: 10.1080/00325481.2016.1218259 To link to this article: http://dx.doi.org/10.1080/00325481.2016.1218259 Accepted author version posted online: 28 Jul 2016.. Published online: 28 Jul 2016.. Submit your article to this journal View related articles View Crossmark data Article Type: Review Safety and efficacy considerations due to misuse of extended-release formulations of stimulant medications Rakesh Jain;1 and Jeffrey G. Stark2 1Department of Psychiatry, Texas Tech Health Sciences Center Medical School at Permian Basin, Midland, Texas, USA; 2Worldwide Clinical Trials, Austin, Texas, USA Running head: misuse of stimulant medications |
